Literature DB >> 7581198

[Antigenic variation and the problem of vaccines against African trypanosomes].

E Pays1.   

Abstract

African trypanosomes evade the immune response of their host through continuous changes of their major surface antigen, the VSG. This antigenic variation is achieved by either alternative activation of different expression sites for the VSG gene, or DNA rearrangements occurring within a given site. Several minor but invariant surface proteins have recently been characterized. This is especially the case for some surface receptors, which appear to be located in an invagination of the plasma membrane termed the flagellar pocket. These proteins may represent useful targets for new vaccination strategies.

Mesh:

Substances:

Year:  1995        PMID: 7581198

Source DB:  PubMed          Journal:  Bull Mem Acad R Med Belg        ISSN: 0377-8231


  4 in total

1.  Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis.

Authors:  Tana Bowling; Luke Mercer; Robert Don; Robert Jacobs; Bakela Nare
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-03-03       Impact factor: 4.077

2.  T. brucei infection reduces B lymphopoiesis in bone marrow and truncates compensatory splenic lymphopoiesis through transitional B-cell apoptosis.

Authors:  Viki Bockstal; Patrick Guirnalda; Guy Caljon; Radhika Goenka; Janice C Telfer; Deborah Frenkel; Magdalena Radwanska; Stefan Magez; Samuel J Black
Journal:  PLoS Pathog       Date:  2011-06-30       Impact factor: 6.823

3.  T. brucei infections abrogate diverse plasma cell-mediated effector B cell responses, independently of their specificity, affinity and host genetic background.

Authors:  Carl De Trez; Shahid Khan; Stefan Magez
Journal:  PLoS Negl Trop Dis       Date:  2020-06-26

4.  Trypanosomiasis-induced B cell apoptosis results in loss of protective anti-parasite antibody responses and abolishment of vaccine-induced memory responses.

Authors:  Magdalena Radwanska; Patrick Guirnalda; Carl De Trez; Bernard Ryffel; Samuel Black; Stefan Magez
Journal:  PLoS Pathog       Date:  2008-05-30       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.